1. ¹Department of Pathology, Genzyme Corporation, Framingham, MA, USA
2. ²Department of Pediatrics, The Children's Hospital of Denver, Denver, CO, USA
3. ³Department of Pathology, Duke University Medical Center, Durham, NC, USA
4. ⁴Division of Medical Genetics, Duke University Medical Center, Durham, NC, USA
5. ⁵Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
6. ⁶Department of Preclinical Biology, Genzyme Corporation, Framingham, MA, USA

Correspondence: Dr BL Thurberg, MD, PhD, Department of Pathology, Genzyme Corporation, One Mountain Road, Framingham, MA 01701-9322, USA. E-mail: Beth.Thurberg@genzyme.com

Received 7 July 2006; Accepted 11 September 2006; Published online 30 October 2006.

Abstract

In Pompe disease, a genetic deficiency of lysosomal acid -glucosidase, glycogen accumulates abnormally in the lysosomes of skeletal, cardiac and smooth muscle, and contributes to clinically progressive and debilitating muscle weakness. The present study involved 8 infantile-onset Pompe patients, treated weekly with 10 mg/kg of recombinant human acid -glucosidase (rhGAA). Muscle biopsies were obtained at baseline, 12 and 52 weeks post-treatment to establish an indicator of efficacy. Several histologic strategies were employed to characterize changes in pre- and post-treatment samples, including high-resolution light microscopy and digital histomorphometry, electron microscopy, capillary density and fiber type analysis, and confocal microscopy for satellite cell activation analysis. Histomorphometric analysis was performed on muscle samples to assess glycogen depletion in response to enzyme replacement therapy (ERT). The extent of glycogen clearance varied widely among these patient samples, and correlated well with clinical outcome. Low glycogen levels, mild ultrastructural damage, a high proportion of type I fibers, and young age at baseline were all features associated with good histologic response. There was no correlation between capillary density and glycogen clearance, and activated satellite cell levels were shown to be higher in post-treatment biopsies with poor histologic responses. This histopathologic study of infantile Pompe disease provides detailed insight into the cellular progression of the disease and its response to therapy while highlighting a number of methodologies which may be employed to assess regression or progression of the associated pathology. As enzyme replacement therapy becomes more prevalent for the treatment of lysosomal storage diseases, such evaluation of post-treatment pathology will likely become a more common occurrence in the daily practice of pathologists.